Side-by-side comparison of AI visibility scores, market position, and capabilities
NY digital health platform with owned pharmacy at $350M revenue in men's health, women's health, and GLP-1 weight management; $876M raised competing with Hims & Hers for DTC telehealth prescription delivery.
Ro is a New York-based digital health platform — backed with $876 million raised from General Catalyst, SignalFire, L Catterton, and others at a peak $7 billion valuation — providing telemedicine consultations, prescription management, and pharmacy-grade medication delivery for men's health (erectile dysfunction, hair loss under the Roman brand), women's health (fertility, menopause under the Rory brand), primary care (Ro Primary Care), and weight management (body program with GLP-1 medications). Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, Ro generated approximately $350 million in revenue in 2024, serving over 2 million patients who have completed consultations through its platforms.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.